Development of the systematic synthetic method of human pseudo-oligosaccharides which have the carbasugar at the nonreducing end
| Project/Area Number |
23750199
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Chemistry related to living body
|
|---|
| Research Institution | Nigata University of Phermacy and Applied Life Sciences |
|---|
Principal Investigator |
MIYAZAKI Tatsuo 新潟薬科大学, 応用生命科学部, 助教 (70410222)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 2-デオキシ-シロ-イノソース / カルバ糖 / 擬似糖 / 擬似糖鎖 / ジカルバグルコビオース |
|---|
| Research Abstract |
Recently, the production of 2-deoxy-scyllo-inosose (DOI) was accomplished by the bioconversion using metabolically engineered E. coli. DOI which is cyclohexanone derivative having four OH groups is suitable as a precursor of carbasugars.
First, 6-O-Ac-carba-beta-D-Glc was synthesized from DOI. Then, we attempted to the synthesis of carbasugars featuring the random pivaloylation of 6-O-Ac-carba-beta-D-Glc, by which partially protected products are obtained at a time. As the results, we accomplished the synthesis of 5a-carba-beta-D-Gal, 5a-carba-beta-D-Man, 5a-carba-beta-D-All and 5a-carba-beta-D-ManNAc by use of the partially protected products.
Additionally, synthesis of 5a,5a'-dicarba-beta-D-isomaltose derivative (47%), 5a,5a'-dicarba-beta-D-maltose derivative (3%) and 5a,5a'-dicarba-alpha,beta-D-trehalose derivative (37%) were achieved by the coupling reaction between carba-beta-D-glucose donor and acceptor under high-concentration condition of substrates at 0 degrees Celsius.
|
Report
(4 results)
Research Products
(20 results)
